Dr. Hatou presented Cellusion business progress in Genesis Digital 2020

Tokyo (December 9th, 2020)-, Dr. Hatou, founder & CEO of Cellusion Inc., presented recent business progress in Genesis Digital 2020 has been held in London, the United Kingdom from December 7th to 15th. As one of promising Japanese healthcare startups, Cellusion participated the workshop named “Japan as a New Investment Target for Life Science Innovation” sponsored by Link-J, Life Science Innovation Network Japan. With our cutting-edge cellular technology, Cellusion will accelerate our research program to deliver novel therapies for bullous keratopathy patients all over the world.

The event has been reported in the following link.
https://www.link-j.org/report/post-3254.html

Details on Genesis Digital 2020, please see the following link, http://www.genesisconference.com/
Details on Link-J, please see the following link, https://www.link-j.org/

For further information, please ask us through contact form in our website.

<About Cellusion Inc.>
Cellusion Inc. is a regenerative medicine startup from Keio University. The mission of Cellusion is to deliver novel therapies for all bullous keratopathy patients by our iPS cells origin corneal endothelial cells mass culture system.

Company ： Cellusion Inc.
CEO ： Shin Hatou, M.D., Ph.D.
Headquarters ：1-13-7 Nihombashi-Muromachi, Chuo, Tokyo 103-0022, JAPAN
Founded ： January 2015
URL ： https://cellusion.jp/en/